Flagship Pioneering
Premier life sciences venture capital and company creation firm. Known for creating companies from scratch, including Moderna (mRNA vaccines). Unique "Pioneering" model conceives, creates, resources, and builds transformative companies internally.
Location
Cambridge, USA
Founded
1999
AUM
$18B+
Investment Range
$25M - $200M
Portfolio Companies
1
Focus
biotech-focused
Fund Stages
seed, series-a, series-b, series-c, growth
Investment Thesis
Flagship Pioneering conceives and creates companies based on breakthrough scientific ideas that can transform human health and sustainability. Their "Pioneering" model develops concepts internally through a rigorous exploration process, then builds companies with dedicated teams and significant resources from inception.
Team
Partners / Managing Directors (Health & Bio Focus)
- Noubar Afeyan, PhD - Co-Founder & CEO
- Stephen Berenson - Managing Partner
- Doug Cole, MD - Managing Partner
- David Epstein - Executive Partner
- Robert Langer, ScD - Executive Partner
Other Key Team Members
- Jason Pontin - General Partner
Focus Areas
- Therapeutics
- mRNA Technology
- Synthetic Biology
- Agriculture
- Sustainability
- Nutrition
- Platform Technologies
Notable Exits
- Moderna - IPO (2018, NASDAQ: MRNA) - COVID-19 vaccine, valued at $100B+ at peak
- Seres Therapeutics - IPO (2015, NASDAQ: MCRB)
- Rubius Therapeutics - IPO (2018, NASDAQ: RUBY)
- Denali Therapeutics - IPO (2017, NASDAQ: DNLI)
- Indigo Agriculture - Major growth (valued at $3.5B+)
Sources
Portfolio Companies
| Name | Location | Founded | Categories |
|---|---|---|---|
| Moderna | Cambridge, Massachusetts, USA | 2010 | therapeuticsbiotech+4 |